Kornimate/medical-research-clean huggingface dataset:
a trial of epilation verses surgery for minor trichiasis

Conditions: Trachomatous Trichiasis

Summary: trachoma is the leading infectious cause of blindness worldwide. recurrent infection by chlamydia trachomatis causes a gradual scarring process of the inner surface of the eyelid (conjunctiva) leading to in-turning of the eyelids (entropion) and lashes touching the eye (trichiasis). the rate of progression and the severity of disease are variable. some people develop severe disease with extensive entropion and trichiasis, whilst others have a mild problem with only a few lashes touching the eye, which does not progress. in more advanced cases there is a broad consensus that the entropion / trichiasis should be corrected by surgery. in mild cases (minor trichiasis: 1-5 lashes touching the eye) the optimal treatment is uncertain. some advocate early surgery to turn the eyelid out for any individual with one or more lashes touching any part of the eye. others consider this to be too early for surgical intervention, as surgery can have a high recurrence rate and complications can arise. instead, they recommend that minor trichiasis can be managed by epilation (pulling out lashes with forceps). in many endemic regions the uptake of surgery is low, with many patients preferring to epilate for mild disease. the primary purpose of this study is to compare the outcome of immediate surgery to regular epilation for the management of minor trichiasis. the epilation would be done by a person with good eyesight using proper epilation forceps.


Eligibility criteria:
inclusion criteria: * minor trichiasis: 1 - 5 lashes touching the eye exclusion criteria: * previous eyelid surgery. * patients with evidence of corneal damage (will be offered surgery).

Keywords: trachoma trichiasis surgery epilation ethiopia
correction of farsightedness in children study

Conditions: Hyperopia; Farsightedness

Summary: the correction of hyperopia in children study (chics) is a placebo-controlled, randomized, masked investigation of the effect of spectacle correction for moderate amounts of hyperopia on visual function, attention, and reading skills in children.

hyperopia (farsightedness) has been reported to be associated with reduced visual perceptual and reading abilities. however, there is controversy regarding whether or not to prescribe for low to moderate amounts of hyperopia. the correction of hyperopia in children study (chics) is a placebo-controlled, randomized, masked investigation of the effect of spectacle correction for moderate amounts of hyperopia on visual function, attention, and reading skills in children.

Eligibility criteria:
inclusion criteria: * age 6-11 years; * at least +1.00d hyperopia (farsightedness); * \< +4.00d hyperopia; * \< 1.00d astigmatism; * \< 1.00d anisometropia (difference between the two eyes); * willing to be randomized; * best corrected visual acuity of 20/25 or better in each eye; * willing to wear eyeglasses full-time; * willing to return for follow-up visits exclusion criteria: * previous wear of glasses or contacts for farsightedness/hyperopia; * eye disease that affects visual function; * amblyopia (lazy eye); * strabismus (eye turn); * history of strabismus surgery; * chronic use of any of the following medications: * antianxiety agents (librium, valium) * antiarrythmic agents (cifenline, cibenzoline) * anticholinergics (motion sickness patch - scopolamine) * bladder spasmolytic (propiverine) * chloroquine * phenothiazines (compazine, mellaril, thorazine) * tricyclic antidepressants (elavil, nortriptyline, tofranil)
vasoactive hormones and oxygen saturation during apneic events in patients with obstructive sleep apnea

Conditions: Obstructive Sleep Apnea

Summary: the mechanisms involved in development and maintenance of hypertension in obstructive sleep apnea are not clarified. we hypothesize that patients with obstructive sleep apnea have an abnormal level of some vasoactive hormones during apneic events during sleep.


Eligibility criteria:
patients with obstructive sleep apnea inclusion criteria: * severe obstructive sleep apnea (apnea-hypopnea index \> 30) exclusion criteria: * drug or alcohol abuse * pregnancy * history or clinical signs of disease in the heart, lungs, brain, liver, kidneys or endocrine organs * diabetes healthy controls inclusion criteria: * apnea-hypopnea index \< 10 exclusion criteria: * drug or alcohol abuse * pregnancy * history or clinical signs of disease in the heart, lungs, brain, liver, kidneys or endocrine organs * diabetes

Keywords: noradrenalin endothelin-1 angiotensin ii arginine vasopressin aldosterone renin atrial natriuretic peptide brain natriuretic peptide blood pressure apnea
efficacy and safety of pembrolizumab pd-l1-positive (>50% of tumor cells), advanced nscl cancer(pembreizh)

Conditions: Carcinoma, Non-Small-Cell Lung; Immunotherapy

Summary: this study was a french multicentric cross-sectional study retrospectively of 108 consecutive advanced nsclc patients with a pd-l1 tps ≥50% and without egfr/alk aberrations treated by pembrolizumab in first line.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed nsclc pd- l1 tps ≥ 50% stage iii and iv who performance status of 0, 1 or 2 adequate organ function exclusion criteria: * previous egfr or alk aberrations positive test for hepatitis b or c virus indicating acute or chronic infection known history of testing positive for human immunodeficiency virus (hiv) severe, uncontrolled autoimmune disease.

Keywords: pembrolizumab first line treatment pdl1 tps > 50% brain efficacy
chuna manual therapy for cervicogenic dizziness

Conditions: Cervicogenic Dizziness

Summary: this is a prospective, pragmatic, assessor-blind, randomized controlled trial to explore the effectiveness of an adjuvant chuna manual therapy (cmt) for cervicogenic dizziness of dizziness handicap inventory (dhi) ≥ 16 at baseline. participants will be randomized and allocated to either cmt combined with usual care (uc) group or uc group with 1:1 ratio. they will receive 12 sessions of cmt or uc treatment for 6 weeks. uc consists of physical therapy and patients education.


Eligibility criteria:
inclusion criteria: * male or female aged between 20 and 70 * neck pain and/or stiffness with dizziness, which is related to movement or positioning of cervical spine * recurring symptom of dizziness over 1 month or more * dizziness handicap inventory ≥ 16 at baseline * informed consent exclusion criteria: * dizziness induced by vestibular disorders (e.g., benign paroxysmal positional vertigo, peripheral vestibulopathy, meniere disease, vestibular neuronitis) * dizziness induced by central nervous system (cns) disorders (e.g., cerebellar ataxia,cerebellum infarction/hemorrhage, demyelination, vertebrobasilar insufficiency, seizure, increased intracranial pressure, parkinson's disease, migraines) * dizziness induced by cardiovascular disorders (e.g., arrhythmia, heart valvular disease, anemia, orthostatic hypotension, coronary artery disease) * dizziness induced by active or uncontrolled disease (e.g., uncontrolled diabetes mellitus, hypertension, respiratory or endocrinological disorders) * dizziness induced by side effects of medications * severe chronic or terminal diseases (malignant cancer, tuberculosis, etc.) * chronic psychiatric diseases under treatment (epilepsy, depression, panic disorder, etc.) * conditions where cmt are forbidden (spinal tumor, acute fracture, infectious spondylopathy, congenital malformations of spine, operation history of spine within 3 months, progressive neurological damage, severe neurological symptoms, spinal fixation devices, syringomyelia, hydrocephaly) * treatment history within 1 week for cervicogenic dizziness (nsaids, steroid, herbal drug, acupuncture, manual therapy) * women of (suspected) pregnancy or breast-feeding * suspicion of alcohol and/or drug abuse * participation in another clinical study within 1 month * difficulty in communicating with the investigators * other reasons for ineligibility of participation
the impact of quetiapine on the drug abuse patterns of addicted schizophrenic patients

Conditions: Schizophrenia; Substance Use Disorders

Summary: the lifetime of substance use disorders in schizophrenia is close to 50%. substance abuse in schizophrenia is associated with negative consequences. unfortunately, there no clear guidelines for the pharmacological treatment of this dual diagnosis population. preliminary results suggest that second-generation antipsychotic drugs (mainly clozapine) may relieve drug cravings in schizophrenia. we performed a 12-week pilot study to evaluate the impact of quetiapine, a second-generation antipsychotic, on substance abuse parameters, psychiatric symptoms and side effects in patients schizophrenia and comorbid substance use disorders. our expectation was a 20 % decrease in drug cravings from baseline to end-point.


Eligibility criteria:
inclusion criteria: * patients with as schizophrenia spectrum disorder * patients with a comorbid substance use disorder exclusion criteria: * patients already on quetiapine or clozapine * patients hospitalized or acutely ill * total score lower than 65 on the panss * pregnancy * female subjects of childbearing potential without adequate contraception * abnormal liver function (hepatic enzymes more than 3 times the upper normal limits) * any clinically meaningful unstable renal, hepatic, cardiovascular, respiratory, cerebrovascular disease or other serious, progressive physical disease.
a study on analgesia and related outcomes for patients with tabacco smoking

Conditions: Current Smokers; Past Smokers; Never Smokers

Summary: numbers of postoperative pca(patient-controlled analgesia) related side effects among current, past and non smokers are determined by comparing and analyzing frequency distributions. to determine whether smokers require more post operative opiate analgesics than others. multivariate analysis will be performed to identify the major and the minor factors predicting the use of postoperative pain therapy. our previous related study showed that the smoker male patients consumed more analgesics than those without smoking, but the female group showed the similar findings. however, the case number, especially the female cases, is underpowered. investigators hope to increase the case number to have a better statistical and clinical significance.


Eligibility criteria:
inclusion criteria: * patients undergoing elective general surgery are assigned to current smokers（n=100） or past smokers（n=100） or never smokers（n=100） according to the questionnaires "fagerstrom test for nicotine dependence" 1 day prior to the surgery. exclusion criteria: * the patients undergoing major thoracic cardiovascular surgery * the patients with significant lung lesion * the patients with conscious disturbance * the patients with allergic history to morphine
albumindialysis in acute pancreatitis

Conditions: Pancreatitis; Multiple Organ Failure

Summary: the incidence of acute pancreatitis has been doubled during last three decades in finland. alcohol is the main cause of acute pancreatitis in finland accounting for 70 % of cases. although the mortality of acute pancreatitis has been decreased it still appears and especially early multiple organ failure is the main cause of all deaths. multiple organ failure in the early course of the disease is thought to be caused by the release of cytokines. molecular adsorbent recirculating system (mars) has shown to decrease mortality in acute alcohol hepatitis and paracetamol intoxication. also it has been shown to improve kidney function due to hypoperfusion and tubulus necrosis and overrule decrease mortality in patients with multiple organ failure due to different reasons. a part of patients with acute alcoholic pancreatitis may have so-called fat liver already on admission. it has been shown that the highest mortality is especially associated those with early liver and kidney failure. mars treatment has never earlier been used in the patients with acute alcoholic pancreatitis and early organ failure. in this study we randomize patients with acute alcoholic pancreatitis and early multiple organ failure (sofa score\>2) to two groups: 1) standard pancreatitis treatment in intensive care unit and 2) standard pancreatitis treatment in intensive care unit with 5 mars sessions.


Eligibility criteria:
inclusion criteria: * severe acute alcoholic pancreatitis with early multiple organ failure (sofa score \>2) exclusion criteria: * if patient or his/her family member refuses, pregnancy.

Keywords: pancreatitis, mars severe acute pancreatitis with early multiple organ failure
driver ablation of persistent atrial fibrillation with severe atrial fibrosis.

Conditions: Persistent Atrial Fibrillation

Summary: this is an open label, randomized parallel control clinical trial, to demonstrate the role of driver mechanism in maintenance substrate of persistent atrial fibrillation with severe atrial fibrosis, and evaluate the clinical outcomes of driver mapping and ablation strategy in patients with persistent atrial fibrillation with severe atrial fibrosis.

this is an open label, randomized parallel control clinical trial. patients with persistent atrial fibrillation with severe atrial fibrosis are 1:1:1 randomized into group a (circumferential pulmonary vein isolation + linear ablation + bi-atrial mapping + driver ablation), group b (circumferential pulmonary vein isolation + linear ablation + posterior wall box isolation) and group c (circumferential pulmonary vein isolation + linear ablation + vein of marshall ethanol infusion). postoperative recurrence rate and other indicators are analyzed to demonstrate the role of driver mechanism in maintenance substrate of persistent atrial fibrillation with severe atrial fibrosis and evaluate the clinical outcomes of driver mapping and ablation strategy in patients with persistent atrial fibrillation with severe atrial fibrosis.

Eligibility criteria:
inclusion criteria: 1. aged 18 to 80 years old; 2. persistent af with severe atrial fibrosis; 3. nonresponse or intolerance to ≥1 antiarrhythmic drug. exclusion criteria: 1. with uncontrolled congestive heart failure; 2. having significant valvular disease; 3. with myocardial infarction or stroke within 6 months of screening; 4. with significant congenital heart disease; 5. ejection fraction was \<40% measured by echocardiography; 6. allergic to contrast media; 7. contraindication to anticoagulation medications; 8. severe pulmonary disease e.g. restrictive pulmonary disease, chronic obstructive disease (copd); 9. left atrial (la) thrombus; 10. having any contraindication to right or left sided heart catheterization; 11. previous atrial fibrillation ablation; 12. presence of an implanted cardioverter-defibrillator; 13. previous history of cardiac surgery; 14. poor general health; 15. life expectancy less than 6 months.

Keywords: persistent atrial fibrillation severe atrial fibrosis driver ablation
stage iii nsclc rwe in chinese patients

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: the objectives of this study are to assess molecular testing, treatment patterns and associated clinical outcomes in chinese patients with treatment-naïve stage iii non-small cell lung cancer (nsclc) in real world setting. this study is a prospective, non-interventional study. it is descriptive in nature and does not attempt to test any specific a priori hypotheses.


Eligibility criteria:
inclusion criteria: * male or female aged 18 years or older. * provision of informed consent prior to any study specific procedures. * histologically or cytologically confirmed locally advanced, stage iii nsclc (according to version 8 of the international association for the study of lung cancer staging manual in thoracic oncology; iaslc staging manual in thoracic oncology). exclusion criteria: * enrolment in studies that prohibit any participation in this observational study. * patients may be concurrently enrolled in unblinded clinical trials, but not blinded clinical trials in which the treatment being administered is unknown. * prior surgery, radiotherapy or systemic therapy for nsclc, including chemotherapy, targeted therapy, anti-angiogenesis, etc.

Keywords: prospective observational stage iii nsclc
investigation of ubamatamab combination therapy in adult participants with platinum-resistant ovarian cancer

Conditions: Ovarian Cancer

Summary: this study is researching an experimental drug called ubamatamab, also referred to as "study drug". the study is focused on patients who have advanced ovarian cancer. the aim of the study is to see how safe, tolerable, and effective the study drug is on its own and in combination with other anti-cancer drugs (bevacizumab, cemiplimab, fianlimab and a standard chemotherapy drug, pegylated liposomal doxorubicin \[pld\]), referred to as "combination drugs'. the study is looking at several other research questions, including: * what side effects may happen from taking the study drug and its experimental combinations * how much study drug and fianlimab is in the blood at different times * whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects) and its combinations


Eligibility criteria:
key inclusion criteria: 1. participants with histologically or cytologically confirmed diagnosis of advanced serous or endometrioid ovarian, primary peritoneal, or fallopian tube cancer (clear cell, mucinous, and carcinosarcoma are excluded) 2. must have progression on prior therapy documented radiographically and must have at least 1 measurable lesion (not previously irradiated) that can be accurately measured by recist 1.1 3. eastern cooperative oncology group (ecog) performance status of 0 or 1 4. adequate organ and bone marrow function, as described in the protocol 5. platinum-resistant ovarian cancer, as described in the protocol key exclusion criteria: 1. major surgical procedure or significant traumatic injury within 4 weeks prior to first dose of study drug(s) 2. documented allergic or acute hypersensitivity reaction attributed to antibody treatments or doxorubicin hydrochloride or components of study drug(s) 3. another malignancy that is progressing or requires active treatment, as described in the protocol 4. untreated or active primary brain tumor, central nervous system (cns) metastases, or spinal cord compression, as described in the protocol 5. uncontrolled infections including but not limited to human immunodeficiency virus, hepatitis b or hepatitis c infection, or diagnosis of immunodeficiency note: other protocol-defined inclusion/exclusion criteria apply

Keywords: platinum resistance fallopian tube cancer primary peritoneal cancer
the peer-delivered "mind. body. voice." program for high school women (mbv) - remote

Conditions: Eating Disorders in Adolescence

Summary: this study will evaluate the impact of a program (called mind. body. voice. or "mbv") that was collaboratively designed by youth, educators, and researchers, informed by the body project (becker et al., 2013; stice et al., 2019), youth participatory action research, an extended co-design process, and previous iterations of the mbv program. the study evaluates the impact of the mbv program on key aspects of mental health and well-being; specifically, body image and disordered eating symptoms, identity and agency, social and self-constructs, physical health and mood at three time points over the course of the 10-week program, which will be offered remotely in response to the covid-19 pandemic. students will be recruited from high schools and will be randomized to receive the mbv program or an assessment-only control group.

eating disorders have the highest mortality rate of any psychiatric condition and are the second leading cause of mental health disability among young women. given that eating disorders have their peak onset during adolescence (ages 16-19), prevention efforts among adolescent women are critical in order to avert the onset of these chronic and disabling disorders. the mbv program targets body image and appearance related pressures, awareness of body sensations, and agency and community building skills. the program consists of 10 weekly sessions and is delivered by peer facilitators. this study will implement and evaluate the mbv program at the high school level in order to examine the extent to which the program influences young women's mental health and well-being, particularly related to eating disorder risk factors and symptoms. utilizing a randomized controlled trial, the study seeks to address the following aims: 1. to examine the impact of the mbv program on key aspects of mental health and well-being; specifically, body image and disordered eating symptoms, identity and agency, social and self- constructs, physical health and mood among participating high school women. 2. to explore young women's experiences of participating in the program, including strengths and limitations and perspectives on specific activities.

Eligibility criteria:
inclusion criteria: * high school women, grades 9-12 exclusion criteria: * prior participation in the body project or mind. body. voice. rct

Keywords: eating disorder prevention peer delivery female adolescence
erector spinae plane block versus classic epidural analgesia in labor

Conditions: Analgesia in Labor

Summary: prosepective,randomized, controlled study enrolling full termed parturients admitted for vaginal delivery. at the sencond stage of labor: 3cm of cervix dilatation, patients will be randomized in 2 groups: * esp group: patients will receive ultrasound guided, bilateral esp block performed at the level of the 3 rd lumbar transverse process. * epidural analgesia group: patients will have a classic lumbar continuous epidural analgesia.

prosepective,randomized, controlled study enrolling full termed parturients admitted for vaginal delivery. at the sencond stage of labor: 3cm of cervix dilatation, patients will be randomized in 2 groups: * esp group: patients will receive ultrasound guided, bilateral esp block performed at the level of the 3 rd lumbar transverse process. * epidural analgesia group: patients will have a classic lumbar continuous epidural analgesia. for the first group: 20 ml of 0,375% isobaric bupivacain solution will be injected bilaterally under ultrasound direct vision. concerning the second group, patients will have a continuous injection of 0,125% bupivacain solution associated to 0,25 mcg of sufentanil/ml through an epidural catheter in the l3-l4 or l4-l5 intervertebral space. for the 2 groups, analgesia will be assessed during all the labor period hourly using the visual analog pain score (vas).

Eligibility criteria:
inclusion criteria: * full termed parturients admitted for vaginal delivery * singleton pregnancy * no contraindications to perimedullar analgesia techniques exclusion criteria: * indication to cesarean section during labor period

Keywords: analgesia, vaginal delivery, esp, epidural